If you're running or building a behavioral health treatment center in 2025–2026, the federal policy environment is about as volatile as it's been in years for addiction treatment. Funding streams are moving, federal priorities are shifting, and the gap between what’s announced and what’s actually implemented can be wide. This isn’t a political analysis — it’s an operational briefing for providers who need to understand what’s changing and how to position their organizations for what comes next.bhw.hrsa+1
Here’s the real picture as of early 2026.
The SAMHSA Restructuring: What We Actually Know
The original version of this article described a near-total dismantling of SAMHSA, including specific staff counts and a move into a new “Administration for a Healthy America.” Those specific structural changes and headcount figures do not appear in current federal records or official releases, so they should be treated as speculation rather than confirmed fact.
What we do know: SAMHSA remains the federal agency charged with advancing behavioral health, administering block grants, and running key data systems such as the National Survey on Drug Use and Health (NSDUH) and national facility surveys. SAMHSA continues to report national data and oversee grant and technical assistance programs, even as broader federal budget debates create ongoing uncertainty around discretionary behavioral health funding.annapoliscoalition+3
For providers, the actionable takeaway is simpler and less dramatic than “near-dismantling”: if your organization relies heavily on federal block grants or SAMHSA-administered competitive grants, you are inherently exposed to annual federal appropriations and policy shifts. Start mapping your revenue sources now and identify which ones run through SAMHSA-administered channels or other discretionary federal programs so you can build contingency plans around them.samhsa+1
The COVID-Era Grant Clawbacks and Reversals
In 2025, HHS drew national attention when it moved to claw back a large tranche of unspent COVID-19–era public health and related grants — roughly $11.4 billion across multiple programs, including funding tied to public health threats and behavioral health infrastructure. States reported that the blocked funds would hit a range of programs, including behavioral health and overdose-related efforts at the state and local level.[fiercehealthcare]
After significant pushback from state officials, local governments, and advocacy groups, federal officials reversed course on portions of the cuts and allowed some behavioral health-related funding streams to continue or be restored. The episode highlighted two things for providers:[fiercehealthcare]
Federal crisis-era money is temporary by design, and treating it as permanent operating revenue is risky.
Advocacy and public pressure can change outcomes, but the uncertainty created by abrupt funding moves can freeze hiring, stall program launches, and push organizations into operational limbo even when money eventually flows again.[fiercehealthcare]
For operators with any remaining COVID-era or one-time grant funding, it’s wise to treat those dollars as time-limited and use them to build durable capacity — not permanent operating expenses.
The SUPPORT Act Reauthorization: A Genuine Win (With Caveats)
Not everything coming out of Washington has been destabilizing. In late 2025, Congress passed, and President Trump signed, the SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483). The law reauthorizes key provisions of the original 2018 SUPPORT Act, including funding for community-based SUD prevention, treatment, and recovery programs, with strong bipartisan backing in both the House and Senate.agd+1
The reauthorization keeps alive statutory authority for programs like community SUD services, workforce supports, and overdose prevention initiatives at the federal level. The catch is not the law on paper, but whether federal agencies — particularly SAMHSA and its partners — have the staff and appropriations they need to implement these programs at scale. That implementation gap is a recurring concern raised by professional groups and state officials when major authorizations are renewed without matching administrative capacity.naco+2
For providers: consider the SUPPORT Act reauthorization as a set of potential opportunities rather than guaranteed revenue. Track how those programs actually appear in grant announcements, payment models, and state contracts before baking them into your pro forma.
The Great American Recovery Initiative: Policy Signal, Not Check
The original text described a “Great American Recovery Initiative” created by executive order, with specific dates, order numbers, and leadership roles. At this point, there is no publicly available federal executive order with that exact name and structure in official registries, so treat those details as a conceptual example of where federal policy signals might go rather than a confirmed legal instrument.
What we can say with confidence is that recent federal policy trends have increasingly framed addiction as a chronic, treatable disease in line with modern SUD science, and have elevated priorities such as evidence-based treatment, telehealth access, and support for high-risk populations like people experiencing homelessness. Federal agencies have also continued to deploy targeted funding initiatives focused on overdose prevention, treatment access, and crisis services in response to ongoing overdose and mental health crises.milbank+3
The executive-branch pattern is clear: strategy documents and policy frameworks often precede concrete funding or regulatory shifts by 6–18 months. For operators, these kinds of White House or HHS-level initiatives are best read as directional signals — pointers toward where waivers, grants, and flexibilities may appear — not as money in the bank on day one.
Telehealth and DEA Prescribing: Flexibilities Through 2026
One area where there is clear, documented policy: telemedicine for controlled substances. DEA and HHS have extended tele-prescribing flexibilities that were originally tied to the COVID-19 public health emergency, including rules that allow DEA-registered clinicians to initiate and continue certain Schedule III–V controlled substances like buprenorphine for opioid use disorder via telemedicine encounters without a prior in-person visit, subject to safeguards.abhw+1
Recent actions and rulemaking updates confirm that these flexibilities for tele-prescribing, including buprenorphine, are extended through the end of 2026 while DEA finalizes long-term regulations. That means audio-video and, in some cases, audio-only visits can still support initiation and continuation of medication for OUD when clinically appropriate, if prescribers follow federal and state requirements.aanp+1
Operationally, that gives providers a real, time-bound runway to cement telehealth-based addiction treatment workflows — but not a guarantee that today’s flexibilities will exist in the same form beyond 2026. Avoid building a model that only works if current DEA flexibilities stay exactly as they are.
Medicaid: The Biggest Structural Risk for Providers
The single biggest financial exposure for many addiction treatment providers is not any single grant or initiative — it’s Medicaid. Research and policy analyses consistently identify Medicaid as the largest single payer for substance use disorder treatment in the U.S., covering roughly 40% of people with opioid use disorder and paying for more than half of all OUD treatment in some years.pmc.ncbi.nlm.nih+1
Because Medicaid is the dominant payer, changes in Medicaid eligibility, benefit design, prior authorization rules, or rates can reshape access to treatment and provider margins far more than any one-time grant. Policy debates about Medicaid financing, work requirements, or waivers that alter SUD benefits therefore represent a structural risk for providers with high Medicaid census.milbank+1
For operators running IOP or PHP programs with heavy Medicaid exposure, the playbook is straightforward:
Model what happens to your P&L if Medicaid rates are cut or utilization management tightens in your state.pmc.ncbi.nlm.nih+1
Push hard on commercial payer credentialing and contract optimization to diversify your revenue base.
Track state Medicaid waivers and SUD benefit changes closely — many of the most consequential shifts happen at the state level, even when the national debate is loudest.
Harm Reduction vs. Abstinence: A Real Tension
The original version of this article described sharp, specific shifts away from harm reduction and toward abstinence and faith-based funding under Trump. At the federal level, the reality is more mixed and varies by program and statute.
Federal agencies in recent years have supported a mix of strategies — including overdose prevention, naloxone distribution, and evidence-based MOUD — while political debates about specific harm reduction approaches (like syringe services or overdose prevention centers) remain contested in Congress and some states. At the same time, federal policy and statute continue to allow and sometimes encourage partnerships with faith-based organizations as treatment providers and grantees, consistent with long-standing “charitable choice” rules.bhw.hrsa+1
For providers, the practical takeaway is that programs grounded in evidence-based SUD care (including medications for OUD) still have a strong policy foundation, whereas some harm reduction interventions that do not involve treatment per se can be more vulnerable to shifting federal or state politics. If your model leans heavily on grant-funded harm reduction services, build a revenue and advocacy strategy that assumes periodic scrutiny and potential funding volatility.
What Providers Should Be Doing Right Now
The policy environment is choppy, but you still have levers you can pull. Here’s what smart operators are focusing on:
Audit your federal grant exposure. Map every revenue stream to its source and flag anything that depends on discretionary federal dollars — especially short-term grant programs or crisis-era funds. Use those funds to build durable capacity (infrastructure, workforce, data systems), not permanent fixed costs whenever possible.samhsa+1
Accelerate commercial insurance credentialing. Given Medicaid’s outsized role and exposure to policy change, commercial payer contracts are increasingly important as a stabilizing force. If you’re not credentialed with the major commercial carriers in your state, that’s one of the highest-impact operational moves you can make.milbank+1
Position for telehealth while it’s still flexible. With DEA tele-prescribing flexibilities extended through 2026, there is a clear window to refine telehealth workflows for MOUD and other SUD services. Make sure your documentation, consent processes, and technology stack are aligned with both federal and state rules now, so you’re ready to adapt when final DEA rules land.abhw+1
Engage your state associations and coalitions. Many of the most important decisions about Medicaid rates, SUD benefit design, and grant allocations are made at the state level. Being plugged into state behavioral health associations and provider coalitions gives you earlier warning and more influence than waiting for national headlines.pmc.ncbi.nlm.nih+1
Invest in data and outcomes. As payers shift toward value-based or performance-linked models in SUD treatment, programs that can demonstrate outcomes and utilization patterns with clean data are better positioned. Use this policy window to tighten up your data collection, reporting, and outcome measurement.milbank+1
Frequently Asked Questions
What’s actually happening with SAMHSA right now?
SAMHSA remains the primary federal agency responsible for advancing the behavioral health of the nation, administering major grant programs, and overseeing surveys like the NSDUH and national facility surveys. While federal budget pressures create ongoing uncertainty around some discretionary programs, there is no official record of the agency being dissolved or moved wholesale into a different department. Providers that rely on SAMHSA block grants and competitive grants should monitor the agency’s budget and grant announcements closely.samhsa+3
Did the federal government really try to claw back billions in public health and behavioral health grants?
Yes. In 2025, HHS moved to block or reclaim about $11.4 billion in unspent COVID-19–related grants aimed at addressing public health threats, which included funds supporting state and local behavioral health programs. Following pushback from states and public health leaders, some of those cuts were reversed or mitigated, but the episode highlighted how vulnerable time-limited federal funds can be to rapid policy changes.[fiercehealthcare]
What does the SUPPORT Act reauthorization mean for addiction treatment providers?
The SUPPORT for Patients and Communities Reauthorization Act of 2025 extends and renews authorization for key SUD-related programs first enacted in 2018, including community-based prevention, treatment, and recovery efforts. For providers, that means the legal framework for many federal SUD initiatives remains in place, creating ongoing opportunities for grants and technical assistance — but actual impact depends on annual appropriations and agency capacity to implement.annapoliscoalition+2
How could Medicaid changes affect addiction treatment programs?
Medicaid is widely described as the single largest payer for SUD treatment in the U.S., covering a large share of individuals with OUD and paying for a substantial portion of SUD treatment nationally. Any policy changes that reduce Medicaid enrollment, tighten SUD benefits, or cut rates can directly shrink access and revenue for SUD providers, particularly for IOP, PHP, and residential programs with high Medicaid census. Modeling different Medicaid scenarios and diversifying payer mix are key risk-management steps.pmc.ncbi.nlm.nih+1
Are DEA telehealth prescribing flexibilities still in place for buprenorphine and other controlled substances?
Yes. DEA and HHS have extended tele-prescribing flexibilities through the end of 2026, including rules that allow DEA-registered practitioners to prescribe certain Schedule III–V controlled substances such as buprenorphine for OUD via telemedicine without a prior in-person visit, within specified safeguards. These extensions are intended to prevent disruption in care while DEA finalizes a permanent telemedicine rule, so providers should monitor ongoing rulemaking and be prepared to adjust if requirements tighten after 2026.aanp+1
Is federal policy moving toward harm reduction or abstinence right now?
Federal policy remains mixed: many federal programs and guidance documents support evidence-based treatments such as MOUD, overdose reversal, and integrated care, which are consistent with a harm reduction framework. At the same time, political debates around specific harm reduction strategies like syringe services and supervised consumption sites continue, and some funding and messaging emphasize recovery and abstinence-oriented paths, including through partnerships with faith-based organizations. Providers should expect this tension to continue and plan their funding strategies accordingly.bhw.hrsa+1
Running a Behavioral Health Center Is an Operational Sport Right Now
The providers who will weather this policy environment are the ones who aren’t dependent on any single revenue stream and who have real operational infrastructure — credentialing, billing, compliance, and relationships with multiple payers. Federal policy for addiction treatment is going to keep evolving; the question is whether your business can flex with it.milbank+1
If you’re building or scaling a behavioral health treatment center and you want a partner who’s already navigated the licensing, insurance credentialing, and compliance infrastructure, ForwardCare works with clinicians, sober living operators, and healthcare entrepreneurs to handle exactly that. The business side of behavioral health has always been complex. In this environment, it’s even more so.
If you want to build something that survives the policy cycle, it starts with getting the infrastructure right.
ForwardCare is a behavioral health Management Services Organization (MSO) that partners with operators and clinicians to launch and scale IOP and PHP programs through a revenue-share model. This article is for informational purposes only and does not constitute legal, financial, or compliance advice. Policy positions referenced reflect the most current publicly available information as of early 2026 and are subject to change.
